Selective oestrogen receptor modulators (SERMs) in postmenopausal women;Selectieve oestrogeenreceptormodulatoren (SERM's) bij postmenopauzale vrouwen

Nederlands Tijdschrift voor Geneeskunde

Volumn 143, Issue 35, 1999, Pages 1771-1776

  Hart, W ^a   Netelenbos, J C ^b  

^a NEDERLANDS TIJDSCHRIFT VOOR GENEESKUNDE   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; ESTROGEN RECEPTOR; LIPOPROTEIN; RALOXIFENE; TAMOXIFEN;

ARTICLE; BONE MINERAL; BREAST CARCINOMA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DRUG STRUCTURE; ENDOMETRIUM CARCINOMA; ESTROGEN THERAPY; FEMALE; FRACTURE; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE;

AGED; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; RALOXIFENE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 0033612952     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995; 332:1589-93.
2. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engström O, et al. Molecular basis of agonism and antagonism of the oestrogen receptor. Nature 1997;389:753-8.
3. Jordan VC. Designer estrogens. Sci Am 1998;279:60-7.
4. Yang NN, Venugopalan M, Hardikar S, Glasebrook A. Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 1996;273:1222-5.
5. Pennisi E. Drug's link to genes reveals estrogen's many sides. Science 1996;273:1171.
6. Kuiper GGJM, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996;93:5925-30.
7. Kuiper GGJM, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997;138:863-70.
8. Onoe Y, Miyaura C, Ohta H, Nozawa S, Suda T. Expression of estrogen receptor beta in rat bone. Endocrinology 1997;138: 4509-12.
9. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, et al. Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun 1998;247: 75-8.
10. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-15.
11. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:71-85.
12. Love RR, Newcomb PA, Wiche DA, Surawicz TS, Jordan VC, Carbone PP, et al. Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst 1990;82:1327-32.
13. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al. Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326: 852-6.
14. Leeuwen FE van, Benraadt J, Coebergh JWW, Kiemeney LALM, Gimbrère CHF, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52.
15. Yang NN, Bryant HU, Hardikar S, Sato M, Galvin RJS, Glasebrook AL, et al. Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen-or raloxifene-mediated bone maintenance. Endocrinology 1996;137:2075-84.
16. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7.
17. Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998;13:1747-54.
18. Ettinger B, Black DM. Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. The effect of raloxifene on the risk of fracture in postmenopausal women with osteoporosis. N Engl J Med [ter perse].
19. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M. Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279:1445-51.
20. Mijatovic V, Netelenbos C, Mooren MJ van der, Valk-de Roo GW de, Jakobs C, Kenemans P. Randomized, double-blind, placebo-controlled study of the effects of raloxifene and conjugated equine estrogen on plasma homocysteine levels in healthy postmenopausal women. Fertil Steril 1998;70:1085-9.
21. Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 1997;96:1964-9.
22. Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery atherosclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998;83:721-6.
23. Husten L. Raloxifene reduces breast-cancer risk. Lancet 1999;353: 44.
24. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women. Results from the MORE randomized trial. JAMA 1999;281:2189-97.
25. Boss SM, Huster WJ, Neild JA, Giant MD, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177:1458-64.